Chemoprevention of Skin Cancer

  • Fiona Zwald
  • David Lambert


This chapter focuses on the use of systemic and topical retinoids in the chemoprevention of skin cancer and will aim to demystify their use in the clinical arena. The use of nonsteroidal anti-inflammatory agents, antioxidants, and tea polyploids will also be addressed. Topical imiquimod, 5-fluoruracil, and photodynamic therapy have been detailed elsewhere (see Chapters 2 and 4).


Xeroderma Pigmentosum Organ Transplant Recipient Solid Organ Transplant Recipient Cyclobutane Pyrimidine Dimer Nonmelanoma Skin Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature. 1994:372:107–110.Google Scholar
  2. 2.
    Rudkin GH, Carlsen BT, Chung CY, et al. Retinoids inhibit squamous cell carcinoma growth and intercellular communication. J Surg Res. 2002;103:183.CrossRefPubMedGoogle Scholar
  3. 3.
    Verma AK. Retinoids in chemoprevention of cancer. J Biol Regul Homeost Agents. 2003;17:92.PubMedGoogle Scholar
  4. 4.
    Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med. 1988;318:1633–1637.CrossRefPubMedGoogle Scholar
  5. 5.
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348;1681–1691.CrossRefPubMedGoogle Scholar
  6. 6.
    Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo controlled study. J Clin Oncol. 1995;13:1933–1938.PubMedGoogle Scholar
  7. 7.
    Euvrard S, Verschoore M, Touraine J, et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet. 1992;340(8810):48–49.Google Scholar
  8. 8.
    Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. QJ Med. 1988:68:717–725.Google Scholar
  9. 9.
    Kelly JW, Sabto J, Gurr FW, et al. Retinoids to prevent skin cancer in organ transplant recipients. Lancet. 1991:338:1407.CrossRefPubMedGoogle Scholar
  10. 10.
    Gibson GE, O’Grady A, Kay EW, et al. Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol. 1998:10:42–47.CrossRefPubMedGoogle Scholar
  11. 11.
    DiGiovanna JJ. Retinoid chemoprevention in the high-risk patient. J Am Acad Dermatol. 1998:39:S82–S85.CrossRefPubMedGoogle Scholar
  12. 12.
    McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol. 1999:140:656–660.CrossRefPubMedGoogle Scholar
  13. 13.
    George R, Weightman W, Russ GR, et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol. 2002;43:269–273.CrossRefPubMedGoogle Scholar
  14. 14.
    Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant. 2005;19:726–734.CrossRefPubMedGoogle Scholar
  15. 15.
    Mehrany K, Weenig RH, Lee KK, et al. Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol. 2005;53:1067–1071.CrossRefPubMedGoogle Scholar
  16. 16.
    Stasko T, Brown MD, Carucci JA, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004;30:642.CrossRefPubMedGoogle Scholar
  17. 17.
    Martinez JC, Otley CC, Stasko T, et al. Transplant Skin Cancer Collaborative. Defining the course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol. 2003;139:301.CrossRefPubMedGoogle Scholar
  18. 18.
    Otley CC, Stasko T, Tope WD, et al. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg. 2006;32:562–568.CrossRefPubMedGoogle Scholar
  19. 19.
    Neuhaus IM, Tope WD. Practical retinoid chemoprophylaxis in solid organ transplant recipients. Dermatol Ther. 2005;18(1):28–33.CrossRefPubMedGoogle Scholar
  20. 20.
    McKerrow KJ, MacKie RM, Lesko MJ, Pearson C. The effect of oral retinoid therapy on the normal human immune system. Br J Dermatol. 1988:119:313–320.CrossRefPubMedGoogle Scholar
  21. 21.
    Tan SR, Tope WD. Effect of acitretin on wound healing in organ transplant recipients. Dermatol Surg. 2004;30:667–673.CrossRefPubMedGoogle Scholar
  22. 22.
    Sekula-Gibbs S, Uptmore D, Otillar L. Retinoids. J Am Acad Dermatol. 2004;50:405–415.CrossRefPubMedGoogle Scholar
  23. 23.
    Yaar M, Gilchrest BA. Photoaging: mechanism, prevention and therapy. Br J Dermatol. 2007;157:874–887.CrossRefPubMedGoogle Scholar
  24. 24.
    Odom R. Managing actinic keratoses with retinoids. J Am Acad Dermatol. 1998;39:S74–S78.CrossRefPubMedGoogle Scholar
  25. 25.
    Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double-blind controlled study. Br J Dermatol. 1987;116:549–552.CrossRefPubMedGoogle Scholar
  26. 26.
    Euvard S, Kanitkas J, Claudy A. Topical retinoids for the management of dysplastic epithelial lesions. In: Skin Diseases after Organ Transplantation. Montrouge: John Libby Eurotext; 1998:P175–P182.Google Scholar
  27. 27.
    Rook AH, Jaworsky C, Nguyen T, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation. 1995;59:714–719.CrossRefPubMedGoogle Scholar
  28. 28.
    Smit JV, Cox S, Blokx WAM, van de Kerkhof PCM, deJongh GJ, deJong EMGJ. Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol. 2002;147:816–818.CrossRefPubMedGoogle Scholar
  29. 29.
    Brenner S, Wolf R, Dascalu DI. Topical tretinoin treatment in basal cell carcinoma. J Dermatol Surg Oncol. 1993;19:264–266.PubMedGoogle Scholar
  30. 30.
    Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigenes: a randomized trial. J Am Acad Dermatol. 2003;49:83–90.CrossRefPubMedGoogle Scholar
  31. 31.
    Phillips TJ, Gottlieb AB, Leyden JJ, et al. Efficacy of 0.1% tazarotene cream for treatment of photodamage. Arch Dermatol. 2002;138:1486–1493.CrossRefPubMedGoogle Scholar
  32. 32.
    Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal cell carcinoma. N Engl J Med. 1999;341:1767–1768.CrossRefPubMedGoogle Scholar
  33. 33.
    Bianchi L, Orlandi A, Campione E, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol. 2004;151:148–156.CrossRefPubMedGoogle Scholar
  34. 34.
    Peris K, Ferrari A, Fargnoli MC, Piccolo D, Chimenti S. Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma. Dermatol Surg. 2005;31:217–220.CrossRefPubMedGoogle Scholar
  35. 35.
    Duvic M, Ni X, Talpur R, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol. 2003;121:902–909.CrossRefPubMedGoogle Scholar
  36. 36.
    Bardazzi F, Bianchi F, Parente G. A pilot study on the use of topical tazarotene to treat squamous cell carcinoma in situ. J Am Acad Dermatol. 2005;52:1102–1104.CrossRefPubMedGoogle Scholar
  37. 37.
    Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis. 1998;19:723–729.CrossRefPubMedGoogle Scholar
  38. 38.
    Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 1999;25:231–240.CrossRefPubMedGoogle Scholar
  39. 39.
    Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog. 2003;38:49–58.CrossRefPubMedGoogle Scholar
  40. 40.
    Tripp CS, Blomme EA, Chinn KS, Hardy MM, LaCelle P, Pentland AP. Epidermal COX-2 induction following ultraviolet irradiation: suggested mechanism for the role of COX-2 inhibition in photoprotection. J Invest Dermatol. 2003;121(4):853–861.CrossRefPubMedGoogle Scholar
  41. 41.
    Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol. 2005;53:966–972.CrossRefPubMedGoogle Scholar
  42. 42.
    Farooq M, Haq I, Qureshi AS. Cardiovascular risks of COX inhibition: current perspectives. Expert Opin Pharmacother. 2008;9:1311–1319.CrossRefPubMedGoogle Scholar
  43. 43.
    Rivers JK, Mclean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol. 1997;133:1239–1242.CrossRefPubMedGoogle Scholar
  44. 44.
    Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open label assessment of the treatment of actinic keratoses with 3.0% diclofenac sodium topical gel. J Drugs Dermatol. 2004;3(4):401–407.PubMedGoogle Scholar
  45. 45.
    Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Aust J Dermatol. 2005;44:40–43.CrossRefGoogle Scholar
  46. 46.
    Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 2.5% diclofenac in 2.5% hyaluronic acid gel. Br J Dermatol. 2002;146:94–100.CrossRefPubMedGoogle Scholar
  47. 47.
    Katiyar SK, Perez A, Mukhtar H. Green tea polyphenol treatment to human skin prevents formation of ultraviolet light B-induced pyrimidine dimers in DNA. Clin Cancer Res. 2000 Oct;6(10):3864–3869.PubMedGoogle Scholar
  48. 48.
    Katiyar SK, Elmets CA. Green tea polyphenolic antioxidants and skin photoprotection. Int J Oncol. 2001 Jun;18(6):1307–1313.PubMedGoogle Scholar
  49. 49.
    Katiyar SK, Bergamo BM, Vyalil PK, Elmets CA. Green tea polyphenols: DNA photodamage and photoimmunology. J Photochem Photobiol B. 2001 Dec 31;65(2–3):109–114.CrossRefGoogle Scholar
  50. 50.
    Yarosh D, Alas LG, Yee V, et al. Pyrimidine dimer removal enhanced by DNA repair liposomes reduces the incidence of UV skin cancer in mice. Cancer Res. 1992;52:4227–4231.PubMedGoogle Scholar
  51. 51.
    Yarosh D, Klein J, O’Connor A, et al. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomized study. Xeroderma Pigmentosum Study Group. Lancet. 2001;357:926–929.CrossRefPubMedGoogle Scholar
  52. 52.
    Wright TI, Spencer JM, Flowers FP. Chemoprevention of non-melanoma skin cancer. J Am Acad Dermatol. 2006;54:933–946.CrossRefPubMedGoogle Scholar
  53. 53.
    Arbeit JM, Riley RR, Huey B, et al. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice. Cancer Res. 1999;59:3610–3620.PubMedGoogle Scholar
  54. 54.
    Ahmad N, Gali H, Javed S, et al. Skin cancer chemopreventive effects of a flavinoid silymarin are mediated via impairment of receptor tryosine kinase signaling and perturbation in cell cycle progression. Biochem Biophys Res Commun. 1998;247:294–301.CrossRefPubMedGoogle Scholar
  55. 55.
    Shyong EQ, Lu Y. Effects of genistein on PUVA induced photodamage. Carcinogenesis. 2002;23:317–321.CrossRefPubMedGoogle Scholar
  56. 56.
    Cheng AL, Hsu CH, Lin HK, et al. Phase 1 clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–2900.PubMedGoogle Scholar
  57. 57.
    Greenlee RT, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin. 2000;50:7–33.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Fiona Zwald
    • 1
  • David Lambert
    • 2
  1. 1.Department of Dermatology, Director of Transplant DermatologyEmory UniversityAtlantaUSA
  2. 2.Division of DermatologyThe Ohio State UniversityColumbusUSA

Personalised recommendations